Abstract
Objectives
Vascular characteristics of tumour and peritumoral volumes of high-grade gliomas change with treatment. This work evaluates the variations of T2*-weighted perfusion parameters as overall survival (OS) predictors.
Methods
Forty-five patients with histologically confirmed high-grade astrocytoma (8 grade III and 37 grade IV) were included. All patients underwent pre- and post-treatment T2*-weighted contrast-enhanced magnetic resonance (MR) imaging. Tumour, peritumoral and control volumes were segmented. Relative variations of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), Ktrans-T2*, kep-T2*, ve-T2* and vp-T2* were calculated. Differences regarding tumour grade and surgical resection extension were evaluated with ANOVA tests. For each parameter, two groups were defined by non-supervised clusterisation. Survival analysis were performed on these groups.
Results
For the tumour region, the 90th percentile increase or stagnation of CBV was associated with shorter survival, while a decrease related to longer survival (393 ± 189 vs 594 ± 294 days; log-rank p = 0.019; Cox hazard-ratio, 2.31; 95% confidence interval [CI], 1.12-4.74). Ktrans-T2* showed similar results (414 ± 177 vs 553 ± 312 days; log-rank p = 0.037; hazard-ratio, 2.19; 95% CI, 1.03-4.65). The peritumoral area values showed no relationship with OS.
Conclusions
Post-treatment variations of the highest CBV and Ktrans-T2* values in the tumour volume are predictive factors of OS in patients with high-grade gliomas.
Key Points
• Vascular characteristics of high-grade glioma tumour and peritumoral regions change with treatment.
• Quantitative assessment of MRI perfusion provides valuable information regarding tumour aggressiveness.
• Quantitative T2*-weighted perfusion parameters can help to predict overall survival.
• Post-treatment variations of CBV and K trans-T2 values are predictive factors of OS.
• Increased values may justify treatment intensification in these patients.
Similar content being viewed by others
Abbreviations
- AIF:
-
Arterial input function
- CBF:
-
Cerebral blood flow
- CBV:
-
Cerebral blood volume
- MTT:
-
Mean transit time
- OS:
-
Overall survival
- TMZ:
-
Temozolamide
- WM:
-
White matter
References
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Chan JL, Lee SW, Fraass BA et al (2002) Survival and failure patterns of high-grade gliomas after 3D conformal radiotherapy. J Clin Oncol 20:1635–1642
Burger PC, Heinz ER, Shibata T, Kleihues P (1988) Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68:698–704
Parsa AT, Wachhorst S, Lamborn KR et al (2005) Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 102:622–628
Watanabe M, Tanaka R, Takeda N (1992) Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 34:463–469
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186
Law M, Yang S, Wang H et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998
Lupo JM, Cha S, Chang SM, Nelson SJ (2005) Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol 26:1446–1454
Cha S (2006) Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 27:475–487
Provenzale JM, York G, Moya MG et al (2006) Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. AJR Am J Roentgenol 187:1036–1042
Emblem KE, Nedregaard B, Nome T et al (2008) Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 247:808–817
Revert Ventura AJ, Sanz-Requena R, Martí-Bonmatí L, Pallardo Y, Jornet J, Gaspar C (2014) The heterogeneity of blood flow on magnetic resonance imaging: a biomarker for grading cerebral astrocytomas. Radiología 56:328–338
Mills SJ, Patankar TA, Haroon HA, Balériaux D, Swindell R, Jackson A (2006) Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 27:853–858
Law M, Young RJ, Babb JS et al (2008) Gliomas. Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498
Hirai T, Murakami R, Nakamura H et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29:1505–1510
Sanz-Requena R, Revert-Ventura A, Martí-Bonmatí L, Alberich-Bayarri A, Garcia-Marti G (2013) Quantitative MR perfusion parameters related to survival time in high-grade gliomas. Eur Radiol 23:3456–3465
Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: mathematical approach and statistical analysis. Magn Reson Med 36:715–725
Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med 36:726–736
Law M, Yang S, Babb JS et al (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25:746–755
Johnson G, Wetzel SG, Cha S, Babb J, Tofts PS (2004) Measuring blood volume and vascular transfer constant from dynamic, T2*-weighted contrast-enhanced MRI. J Magn Reson Imaging 51:961–968
Henry RG, Vigneron DB, Fischbein NJ et al (2000) Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 21:357–366
Price SJ, Green HAL, Dean AF, Joseph J, Hutchinson PJ, Gillard JH (2011) Correlation of relative cerebral blood volume with cellularity and proliferation in high grade gliomas: an image-guided biopsy study. AJNR Am J Neuroradiol 32:50–56
Blasel S, Franz K, Ackermann H, Weidauer S, Zanella F, Hattingen E (2011) Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery. J Neuro-Oncol 103:575–584
Jain R, Polsson L, Gutman D et al (2014) Outcome prediction in patients with glioblastoma by using imaging, clinical and genomic biomarkers: focus on the non-enhancing component of the tumor. Radiology 272:484–493
Akbari H, Macyszyn L, Da X et al (2014) Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity. Radiology 273:502–510
Cao Y, Tsien CI, Nagesh V et al (2006) Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int J Radiat Oncol Biol Phys 64:876–885
Mangla R, Singh G, Ziegelitz D et al (2010) Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256:575–584
Coban G, Mohan S, Kural F, Wang S, O’Rourke DM, Poptani H (2015) Prognostic value of dynamic susceptibility contrast-enhanced and diffusion-weighted MR imaging in patients with glioblastomas. AJNR Am J Neuroradiol 36:1247–1252
Jabehdar Maralani P, Melhem ER, Wang S et al (2015) Association of dynamic susceptibility contrast enhanced MR perfusion parameters with prognosis in elderly patients with glioblastomas. Eur Radiol 25:2738–2744
Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR (2006) Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol 27:402–408
Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ (2012) Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology 264:834–843
Law M, Young R, Babb J, Pollack E, Johnson G (2007) Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. AJNR Am J Neuroradiol 28:761–766
De Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-therapy changes in malignant glioma can mimic tumor progression. Neurology 63:535–537
Cao Y, Nagesh V, Hamstra D et al (2006) The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res 66:8912–8917
Bag AK, Cezayirli PC, Davenport JJ et al (2014) Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. J Neuro-Oncol 120:361–370
Jackson JR, Fuller GN, Abi-Said D et al (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-Oncology 3:193–200
Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 25:2466–2474
Acknowledgements
The scientific guarantor of this publication is Dr. Luis Marti-Bonmati.
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
This study has received funding by the Sociedad Española de Radiología (Becas SERAM Industria 2013). No complex statistical methods were necessary for this paper.
Institutional Review Board approval was obtained. Written informed consent was obtained from all subjects (patients) in this study. Methodology: retrospective, diagnostic or prognostic study, multicentre study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sanz-Requena, R., Revert-Ventura, A.J., García-Martí, G. et al. Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma. Eur Radiol 27, 3392–3400 (2017). https://doi.org/10.1007/s00330-016-4699-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-016-4699-2